What Does the Leukorrhea Panel Look For?
A leukorrhea panel screens for the three most common infectious causes of vaginal discharge—Candida (yeast), Trichomonas vaginalis, and Gardnerella (bacterial vaginosis)—while also assessing vaginal cleanliness grade and estrogen status. 1
Core Components of the Panel
The leukorrhea panel is a rapid, office-based diagnostic tool that answers eight essential questions in approximately two minutes using specimens collected during pelvic examination 1:
Primary Pathogens Detected:
- Candida albicans (yeast infection)
- Trichomonas vaginalis (parasitic infection)
- Gardnerella/Clue cells (bacterial vaginosis indicator)
Additional Assessments:
- Vaginal cleanliness grade (Grade I-IV, with III-IV considered abnormal) 2
- Inflammatory markers (presence of white blood cells/leukocytes)
- Estrogen deficiency indicators (particularly relevant in perimenopausal women)
- Overall vaginal health status 1
Clinical Context and Screening Recommendations
While the leukorrhea panel focuses on common vaginal pathogens, all patients being evaluated for vaginal discharge should also be tested for gonorrhea and chlamydia 3. This is critical because:
- Gonococcal and chlamydial infections are frequently asymptomatic in women
- These infections can lead to serious complications like pelvic inflammatory disease (PID), infertility, and ectopic pregnancy if untreated
- Co-infection rates are high enough to warrant routine dual screening
Testing Methodology
The panel uses normal saline wet mount microscopy 2, which allows immediate visualization of:
- Motile trichomonads
- Budding yeast and pseudohyphae
- Clue cells (epithelial cells covered with bacteria)
- White blood cell counts
This approach is cost-effective (approximately $2 in supplies) and provides rapid results during the clinical encounter 1.
Important Clinical Pitfall
Do not rely on the leukorrhea panel alone for STD screening. The panel does not detect Neisseria gonorrhoeae or Chlamydia trachomatis, which require separate nucleic acid amplification testing (NAAT) or culture 3. Women at increased risk (age <25 years, multiple partners, inconsistent condom use, previous STDs) require comprehensive STD screening beyond the basic leukorrhea panel.